Agata Sołdatow

GSK today announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to 12 innovative medicines, adding significant new growth opportunities to the company beyond 2031. The programmes were selected to complement GSK’s extensive Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline, and assessed for their potential best- or first-in class profiles. GSK will pay $500 million in upfront fees across the agreements.    The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong, Macau and Taiwan) for a potential best-in-class, PDE3/4 inhibitor in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an add-on maintenance treatment, irrespective of background therapy. The addition of HRS-9821 supports GSK’s ambition to treat patients across the widest spectrum of COPD by including those who face continued dyspnoea or who are unlikely to receive inhaled corticosteroids or biologics, based on their disease profile.    HRS-9821 has demonstrated potent PDE3 and PDE4 inhibition, leading to increased bronchodilation and anti-inflammatory effects in early clinical and preclinical studies. In addition, HRS-9821 provides the opportunity for a convenient dry-powder inhaler (DPI) formulation that strategically fits GSK’s established inhaled portfolio. The agreements also include a pioneering scaled collaboration to generate up to 11 programmes in addition to HRS-9821, each with its own financial structure. Hengrui Pharma will lead the development of these programmes up to completion of phase I trials, including patients outside of China. GSK will have the exclusive option to further develop and commercialise each programme worldwide (excluding mainland China, Hong Kong, Macau and Taiwan), at the end of phase I or earlier at GSK’s election, as well as certain programme substitution rights. Tony Wood, Chief Scientific Officer, GSK: "We're delighted to announce these exciting agreements with Hengrui Pharma which complement our already-extensive pipeline. This deal reflects our strategic investment in programmes that address validated targets, increasing the likelihood of success, and with the option to advance those assets with the greatest potential for patient impact.”    Frank Jiang, Executive Vice President and Chief Strategy Officer of Hengrui Pharma: "This strategic collaboration with GSK marks yet another significant milestone in Hengrui’s globalisation journey and our mission to innovate and deliver higher-quality, cutting-edge therapies for patients worldwide. GSK brings additional R&D expertise, a robust global clinical network, and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programs to overseas markets, potentially delivering breakthrough treatments to patients globally."  #collaboration #HengruiPharma #GSK #AheadTogether

361

2件のコメント

SK bioscience CEO Jaeyong Ahn joined SK Group Chairman Tae-won (Tony) Chey in a meeting with Bill Gates in Seoul to discuss expanding collaboration in vaccine R&D and global public health. Building on over a decade of trusted partnership with the Gates Foundation, both sides reaffirmed their commitment to advancing next-generation vaccines and pandemic preparedness, with a shared focus on protecting vulnerable populations in low- and middle-income countries. From typhoid and pediatric enteritis vaccines to Korea’s first COVID-19 vaccine, SK bioscience has worked closely with the Gates Foundation to deliver life-saving solutions. We will continue to expand our vaccine portfolio and strengthen accessibility worldwide. 🌍💉 Read more: https://lnkd.in/gqyuwYNa

558

2件のコメント

2 Minutes of Insightful Dialogue with a Life Science expert : Cracking the Asian Cosmeceuticals Market This August, I sat down with Laurent Cibot 罗朗 🇫🇷, EVP at Inderma with 20+ years of Asia expertise, to unpack what it really takes to succeed in Asia’s fast-evolving cosmeceuticals space. From navigating complex regulations (Japan’s “quasi-drugs” vs. China’s shifting CSAR) to meeting ultra-savvy, results-driven consumers, Asia is a market like no other. Key takeaways: - Regulatory fragmentation is the #1 barrier. - Consumers expect science-backed results, fast. - Digital tools and doctor influencers are non-negotiable. - Localisation is king, from formula to texture to trust. Want to break into Asia’s booming beauty market? Start with credibility, not hype. #LifeSciences #Cosmeceuticals #AsiaMarket #DigitalHealth

40

3件のコメント